We are live on ! Find out more
PCVX icon

Vaxcyte
PCVX

251 hedge funds and large institutions have $8.13B invested in Vaxcyte in 2024 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 102 increasing their positions, 77 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 18

37% more call options, than puts

Call options by funds: $16.7M | Put options by funds: $12.2M

32% more repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 77

25% more capital invested

Capital invested by funds: $6.51B → $8.13B (+$1.63B)

13% more funds holding

Funds holding: 223 → 251 (+28)

0.97% more ownership

Funds ownership: 108.91% → 109.87% (+0.97%)

14% less funds holding in top 10

Funds holding in top 10: 14 → 12 (-2)

Holders
251
Holders Change
+28
Holders Change %
+12.56%
% of All Funds
3.62%
Holding in Top 10
12
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-14.29%
% of All Funds
0.17%
New
48
Increased
102
Reduced
77
Closed
18
Calls
$16.7M
Puts
$12.2M
Net Calls
+$4.53M
Net Calls Change
-$2.42M

Top Buyers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$160M
2
DGM
Darwin Global Management
Jersey
+$150M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$142M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$89M
5
PBA
Paradigm Biocapital Advisors
New York
+$85.9M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$40.5M
2
Millennium Management
Millennium Management
New York
-$33.5M
3
VPC
Vestal Point Capital
New York
-$33M
4
GPP
Great Point Partners
Connecticut
-$22.6M
5
Pictet Asset Management
Pictet Asset Management
Switzerland
-$19.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
BAAM
151
Baker Avenue Asset Management
California
$932K -$9.49K -137 -1%
PL
152
Parkwood LLC
Ohio
$926K -$133K -1,925 -12%
CCIA
153
Campbell & Co Investment Adviser
Maryland
$920K -$952K -13,746 -51%
AG
154
Algert Global
California
$909K -$74.8K -1,080 -8%
CIP
155
Chartwell Investment Partners
Pennsylvania
$906K +$21.8K +315 +2%
BG
156
Bellevue Group
Switzerland
$905K -$177K -2,556 -16%
Natixis Advisors
157
Natixis Advisors
Massachusetts
$904K -$55.7K -805 -6%
GT
158
Glenmede Trust
Pennsylvania
$810K -$253K -3,659 -24%
AIP
159
Ameritas Investment Partners
Nebraska
$720K +$72.7K +1,050 +11%
AQR Capital Management
160
AQR Capital Management
Connecticut
$719K -$109K -1,568 -13%
ECU
161
Eisler Capital (US)
New York
$714K +$724K +10,454 New
Calamos Advisors
162
Calamos Advisors
Illinois
$694K +$704K +10,165 New
Public Employees Retirement Association of Colorado
163
Public Employees Retirement Association of Colorado
Colorado
$684K – – –
State Board of Administration of Florida Retirement System
164
State Board of Administration of Florida Retirement System
Florida
$647K -$659K -9,510 -36%
HS
165
HighVista Strategies
Massachusetts
$637K – – –
HIS
166
Harvest Investment Services
Illinois
$592K +$600K +8,663 New
LPL Financial
167
LPL Financial
California
$585K -$152K -2,202 -20%
SAM
168
Sectoral Asset Management
Quebec, Canada
$581K +$31.2K +450 +6%
HCA
169
Harbor Capital Advisors
Illinois
$560K +$567K +8,193 New
LCM
170
Legato Capital Management
California
$547K -$290K -4,187 -34%
Allianz Asset Management
171
Allianz Asset Management
Germany
$512K -$173K -2,500 -25%
US Bancorp
172
US Bancorp
Minnesota
$512K -$626K -9,035 -55%
PNC Financial Services Group
173
PNC Financial Services Group
Pennsylvania
$503K +$26.2K +378 +5%
SRL
174
Scientech Research LLC
New Jersey
$498K +$279K +4,034 +124%
Truist Financial
175
Truist Financial
North Carolina
$471K -$132K -1,911 -22%
5 6
7
8 9

PCVX Hedge Fund Activity: Q1 2024 in Review

251 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q1 2024, worth a combined $8.13B — up 25% from $6.51B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new PCVX positions and 18 closed out — a net gain of 30 holders — while 102 added to existing stakes and 77 trimmed.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $160M. The largest seller was Morgan Stanley, cutting an estimated $40.5M.

  • 251 institutional investors held Vaxcyte (PCVX) as of Q1 2024, up from 223 in Q4 2023.
  • Funds reported $8.13B of Vaxcyte stock for Q1 2024, up 25% quarter-over-quarter.
  • 48 funds opened new Vaxcyte positions in Q1 2024 and 18 closed out, a net change of +30 holders.
  • The largest Vaxcyte buyer in Q1 2024 was T. Rowe Price Investment Management, an estimated $160M added.
  • The largest Vaxcyte seller in Q1 2024 was Morgan Stanley, an estimated $40.5M sold.

Based on aggregated 13F filings for Q1 2024.